EU/3/15/1585

About

On 14 December 2015, orphan designation (EU/3/15/1585) was granted by the European Commission to Rare Partners srl Impresa Sociale, Italy, for sirolimus for the treatment of beta-thalassaemia intermedia and major.

The sponsor’s address was updated in May 2020.

Key facts

Active substance
Sirolimus
Disease / condition
Treatment of beta thalassaemia intermedia and major
Date of first decision
14/12/2015
Outcome
Positive
EU designation number
EU/3/15/1585

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Rare Partners srl Impresa Sociale
Via Giovanni Boccaccio 20
20123 Milano
Italy
Tel. +39 034 0704 5710
Fax +39 024 507 4463
E-mail: info@rarepartners.org

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating